Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

SHE:002399 Revenue

Shenzhen Hepalink Pharmaceutical Group had revenue of 1.22B CNY in the quarter ending September 30, 2026, a decrease of -11.60%. This brings the company's total for the last twelve months to 5.08B, down -6.01% year-over-year. In the year 2025, Shenzhen Hepalink Pharmaceutical Group had annual revenue of 5.48B with 3.75% growth. That makes Shenzhen Hepalink Pharmaceutical Group the 8,993rd largest company in the world by revenue and 1,415th in China.

• Revenue (ttm): 5.08B
• Revenue Growth: -6.01%
• P/S Ratio: 2.47
• Revenue / Employee: 2.36M
• Employees: 2,150
• Market Cap: 12.53B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Preparations 7.70B 63.0%
• Active Pharmaceutical Ingredient (API) 3.20B 26.2%
• CDMO 1.03B 8.5%
• Others 277.99M 2.3%

By Geography

Chart

• Europe 2.73B 49.9%
• United States of America 1.34B 24.5%
• Other Countries/Regions 995.55M 18.2%
• Mainland China 393.95M 7.2%
• Hong Kong 7.91M 0.1%

Fiscal year ended Dec 31, 2025 See the full SHE:002399 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	5.48B	198.27M	3.75%
Dec 31, 2024	5.28B	-150.26M	-2.77%
Dec 31, 2023	5.43B	-1.73B	-24.14%
Jan 1, 2023	7.16B	794.23M	12.48%
Jan 1, 2022	6.37B	1.03B	19.38%

Data Source: S&P Global Market Intelligence Last updated: Oct 29, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 4, 2026

Data Sources Report a data error